Vnitr Lek 2020, 66(3):190-195 | DOI: 10.36290/vnl.2020.049

Euvascor - early intervention of hypertension and dyslipidaemia (dual combination of atorvastatin and perindopril)

Lukáš Zlatohlávek
3 . interní klinika 1. LF UK a VFN, Praha

Over the last 30 years, the number of cardiovascular causes of death has decreased, but Cardi-ovascular Disease has been the leading cause of mortality and morbidity in the Czech Republic. In spite of a clear decline, this still persisting primacy is due to the failure to achieve the target recommended values and the late initiation of pharmacotherapy. We know that lifetime LDL cholesterol exposure reduced by 1 mmol/l is associated with a 54% reduction in the incidence of coronary events. A lifetime lower systolic BP of 10 mmHg is associated with a 45% reduction in the incidence of coronary events. Lifetime exposure to a combination of LDL cholesterol lower by 1 mmol/l and systolic BP lower by 10 mm Hg was associated with a 78% reduction in the lifetime risk of coronary events and a 68% reduction in the lifetime risk of a cardiovascular death. The benefits of this intervention increase over time - long-term exposure to even a small difference in LDL cholesterol and systolic pressure can significantly reduce the lifetime risk of cardiovascular disease, if it persists over the time. In this respect, the recently presented new common ESC/ EAS recommendations from 2019, that is to focus treatment on dyslipidemia on a lifelong approach of reducing CV risk and therapeutic lifelong intervention with aim to achieve lower LDL cholesterol levels at all risk levels. Perindorpil antihypertezive and atorvasatin hypolipidemic drugs, ideally in a fixed combination, are able to reduce the patient's CV risk early. The ideal motivation for adherence of patients is the introduced concept of the vascular age, respectively the aging.

Keywords: atherosclerosis risk factors, dyslipidemia, arterial hypertension, fixed combination therapy, early intervention, vascular age.

Published: May 26, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zlatohlávek L. Euvascor - early intervention of hypertension and dyslipidaemia (dual combination of atorvastatin and perindopril). Vnitr Lek. 2020;66(3):190-195. doi: 10.36290/vnl.2020.049.
Download citation

References

  1. Zlatohlávek L, et al. Klinická dietologie a výživa, CurrentMedia, Praha, 2016.
  2. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk, European Heart Journal (2019) 00, 1-78.
  3. Lipitor (atorvastatin calcium) tablets. Parke‑Davis, Moris Plains, USA, 1996 (Data on file). Malhotra HS, Goa K. Atorvastatin. An updated review of its pharmacological properties and use in dyslipidaemia. Drugs 2001; 61: 1835-1881. Go to original source... Go to PubMed...
  4. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower‑than‑average cholesterol concentrations, in the Anglo‑Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT‑LLA): a multicentre randomised controlled trial. Lancet. 2003 Apr 5; 361(9364): 1149-1158.Další literatura u autoraa na www.casopisvnitrnilekarstvi.cz Go to original source... Go to PubMed...
  5. Gupta A, Mackay J, Whitehouse A, et al. ASCOT Legacy study. Lancet 2018; 392: 1127-1137. Go to original source... Go to PubMed...
  6. Komukai et al. Change in Plaque Characteristics with Atorvastatin. Easy‑FIT study. JACC VOL. 64 No 21, 2014: 2207-2217. Go to original source... Go to PubMed...
  7. Fox KM. The EURopean Trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double‑blind, placebo‑controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788. Go to original source... Go to PubMed...
  8. Bruining N, deWinter S, Roaelandt JR, et al. The Perspective study, Coron Artery Dis 2009, 20: 409-414. Go to original source... Go to PubMed...
  9. PROGRESS Collaborative Group, Randomised trial of a perindopril‑based blood‑pressure‑lowering regiment among 6105 individuals with previous stroke or transient ischaemic attack, Lancet 2001; 358: 1033-1041. Go to original source... Go to PubMed...
  10. Patel A, Group AC, mac Mahn SC, et al. Eff ects of a fi xed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial, Lancet 2007; 370: 829-840. Go to original source... Go to PubMed...
  11. van Vark LC, Bertrand M, Akkerhuis KM, et al. Angiotensin converting enzyme inhibitors reduce mortality in hypertension: a meta analysis of randomized clinical trials of renin angiotensin aldosterone system inhibitors involving 158,998 patients. Eur Heart J 2012; 33: 2088- 2097. Go to original source... Go to PubMed...
  12. Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (The CURVES Study). Am J Cardiol 1998; 81: 582-587. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.